Author

Vani Lakshminarayanan

Observed names: V. Lakshminarayanan, Vani LAKSHMINARAYANAN

Observed institutions: Johnson & Johnson (United States), Mayo Clinic, Mayo Clinic in Arizona, Janssen Research & Development (United States)

ORCID: 0000-0002-1750-7858

Observed ORCID: 0000-0002-1750-7858

OpenAlex ID: A5063263178

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

2011 · Vani Lakshminarayanan, Pamela Thompson, et al. · Proceedings of the National Academy of Sciences · 301

Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist

2014 · Abu‐Baker M. Abdel‐Aal, Vani Lakshminarayanan, et al. · ChemBioChem · 64

Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide

2015 · Pamela Thompson, Vani Lakshminarayanan, et al. · Chemical Communications · 60

MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

2016 · Vani Lakshminarayanan, Nitin T. Supekar, et al. · PLoS ONE · 54

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials

2021 · Kristen Sweet, Qingxuan Song, et al. · RMD Open · 38

Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide

2017 · Nitin T. Supekar, Vani Lakshminarayanan, et al. · ChemBioChem · 18

Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes

2016 · Latha Pathangey, Vani Lakshminarayanan, et al. · Biomolecules · 11

Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study

2025 · Irving T. C. Ling, Stanley J. Marciniak, et al. · Therapeutic Advances in Musculoskeletal Disease · 5

Op0229 Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (discover-1 and Discover-2)

2020 · S. Siebert, I. Mcinnes, et al. · Annals of the Rheumatic Diseases · 1

Tri-component MUC1 glycopeptide vaccine induced both humoral and cellular immune responses in MUC1.Tg mice with MMT tumor. (48.20)

2011 · Vani Lakshminarayanan, Pamela Thompson, et al. · The Journal of Immunology · 1

Pharmacodynamic Effect of Nipocalimab in Warm Autoimmune Hemolytic Anemia (waiha) and Correlation With Clinical Improvement

2026 · Bruno FATTIZZO, Irina MURAKHOVSKAYA, et al. · Hematology Transfusion and Cell Therapy

Abstract 2403: Glycosylated (Tn) and Anchor-Modified MUC1 Peptide Vaccines Induce Effective Anti tumor Immunity and Break Tolerance in MUC1 Transgenic Mice

2010 · Vani Lakshminarayanan, Judy M. Bradley, et al. · Cancer Research

Examination of Immune Competence in Breast Cancer Patients at Six Months Post Surgery and Adjuvant Therapy through Assessment of T Cell and Dendritic Cell Functionality.

2009 · S. Gendler, L. Pathangey, et al. · Cancer Research

Works count: 13

Citation count: 553

H-index: 7

I10-index: 7